- Home
- SNCR vs MAIA Comparison
SNCR vs MAIA Comparison
Compare SNCR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- MAIA
- Stock Information
- Founded
- SNCR 2000
- MAIA 2018
- Country
- SNCR United States
- MAIA United States
- Employees
- SNCR N/A
- MAIA N/A
- Industry
- SNCR EDP Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SNCR Technology
- MAIA Health Care
- Exchange
- SNCR Nasdaq
- MAIA Nasdaq
- Market Cap
- SNCR 137.5M
- MAIA 62.4M
- IPO Year
- SNCR 2006
- MAIA 2022
- Fundamental
- Price
- SNCR $11.25
- MAIA $2.82
- Analyst Decision
- SNCR
- MAIA
- Analyst Count
- SNCR 0
- MAIA 0
- Target Price
- SNCR N/A
- MAIA N/A
- AVG Volume (30 Days)
- SNCR 81.2K
- MAIA 60.0K
- Earning Date
- SNCR 11-12-2024
- MAIA 11-05-2024
- Dividend Yield
- SNCR N/A
- MAIA N/A
- EPS Growth
- SNCR N/A
- MAIA N/A
- EPS
- SNCR N/A
- MAIA N/A
- Revenue
- SNCR $167,615,000.00
- MAIA N/A
- Revenue This Year
- SNCR $7.76
- MAIA N/A
- Revenue Next Year
- SNCR $5.83
- MAIA N/A
- P/E Ratio
- SNCR N/A
- MAIA N/A
- Revenue Growth
- SNCR 33.39
- MAIA N/A
- 52 Week Low
- SNCR $2.70
- MAIA $0.82
- 52 Week High
- SNCR $15.46
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- SNCR 43.11
- MAIA 50.98
- Support Level
- SNCR $10.45
- MAIA $2.36
- Resistance Level
- SNCR $11.44
- MAIA $2.72
- Average True Range (ATR)
- SNCR 0.57
- MAIA 0.22
- MACD
- SNCR -0.06
- MAIA 0.02
- Stochastic Oscillator
- SNCR 31.58
- MAIA 72.28
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a leading provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and highly scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.